72 related articles for article (PubMed ID: 1313268)
1. Cyclic AMP phosphodiesterase from human heart and drug action.
Tanaka T; Masuoka H; Ito M; Nakano T; Naka M; Hidaka H
Adv Second Messenger Phosphoprotein Res; 1992; 25():373-81. PubMed ID: 1313268
[No Abstract] [Full Text] [Related]
2. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes.
Sugioka M; Ito M; Masuoka H; Ichikawa K; Konishi T; Tanaka T; Nakano T
Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep; 350(3):284-93. PubMed ID: 7824045
[TBL] [Abstract][Full Text] [Related]
3. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue.
Moore JB; Combs DW; Tobia AJ
Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
5. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney.
Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
J Cardiovasc Pharmacol; 1990 Feb; 15(2):302-7. PubMed ID: 1689427
[TBL] [Abstract][Full Text] [Related]
6. Resolution of soluble rat cardiac phosphodiesterases by high performance liquid chromatography.
Bode DC; Kanter JR; Brunton LL
Second Messengers Phosphoproteins; 1988-1989; 12(5-6):235-40. PubMed ID: 2856111
[TBL] [Abstract][Full Text] [Related]
7. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
Picq M; Dubois M; Prigent AF; Némoz G; Pacheco H
Biochem Int; 1989 Jan; 18(1):47-57. PubMed ID: 2541724
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride.
Sellin LC; Alajoutsijärvi A; Törnquist K; Fraser M; Pippuri A; Ojala I
Arzneimittelforschung; 1988 Dec; 38(12):1787-9. PubMed ID: 2854467
[TBL] [Abstract][Full Text] [Related]
11. A novel class of cardiotonic agents: synthesis and biological evaluation of pyridazino[4,5-b]indoles with cyclic AMP phosphodiesterases inhibiting properties.
Monge A; Aldana I; Losa MJ; Font M; Castiella E; Frechilla D; Cenarruzabeitia E; Martinez de Irujo JJ; Lopez-Unzu J; Alberdi E
J Pharm Sci; 1993 May; 82(5):526-30. PubMed ID: 8395600
[TBL] [Abstract][Full Text] [Related]
12. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor.
Erhardt PW; Hagedorn AA; Sabio M
Mol Pharmacol; 1988 Jan; 33(1):1-13. PubMed ID: 2826995
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for potent and selective inhibition of low-Km, cyclic-AMP-specific phosphodiesterases.
Robertson DW; Boyd DB
Adv Second Messenger Phosphoprotein Res; 1992; 25():321-40. PubMed ID: 1313265
[No Abstract] [Full Text] [Related]
14. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Harrison SA; Chang ML; Beavo JA
Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
[TBL] [Abstract][Full Text] [Related]
15. Interactions between inotropic drugs.
Ducart A
Acta Anaesthesiol Belg; 2001; 52(4):377-84. PubMed ID: 11799570
[No Abstract] [Full Text] [Related]
16. [Use of dye affinity chromatography in the purification of cytosol phosphodiesterases (type II) from the bovine heart].
Dettmer D; Greiner J; Hofmann E
Z Med Lab Diagn; 1987; 28(8):403-9. PubMed ID: 2830734
[No Abstract] [Full Text] [Related]
17. [Levosimendan].
Michels G; Herzig S; Hoppe UC
Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
[No Abstract] [Full Text] [Related]
18. Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney.
Epstein PM; Strada SJ; Sarada K; Thompson WJ
Arch Biochem Biophys; 1982 Oct; 218(1):119-33. PubMed ID: 6293381
[No Abstract] [Full Text] [Related]
19. [Inhibition of cyclic nucleotide phosphodiesterase from rabbit heart by hydroxypyridines].
Polyansky NB; Smirnov LD; Shvedova AA; Kagan VE; Tkachuk VA
Vopr Med Khim; 1983; 29(1):123-7. PubMed ID: 6301154
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
